KiOmed Pharma

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s KiOmed Pharma SA, securing exclusive development and commercialization rights to KiOmedine One for the treatment of osteoarthritis in mainland China, Macau, and Taiwan. Under the agreement, Hansoh will be responsible for the development, regulatory filing,…